AZN’s oncology pipeline is weighted toward “targeted” agents rather than I-O, so I’m not sure “exciting” is the most apt description. Imfinzi is distant fourth in the PD(L)-1 category.
I would use the term "innovative" -- they are addressing a broad range of novel targets, most of which aren't me-toos.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.